BioMarin Pharma (BMRN) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $127 at JPMorgan
February 23, 2018 7:27 AM ESTJPMorgan lowered its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $127.00 (from $129.00) while maintaining a Overweight rating.
... MoreBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $100 at Citi Following 4Q
February 23, 2018 7:11 AM ESTCiti raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $100.00 (from $96.00) while maintaining a Buy rating following the company's 4Q. Results were in-line with consensus estimates on the top-line, while the bottom-line was a miss due to tax impact.
The company... More
